ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 817

Feasibility of Using a Pharnacist-Based Gout Management Clinic to Improve Serum Uric Acid in Gout Patients an a Large Prepaid Health Plan

Robert D. Goldfien1, Michele S. Ng2, Goldie M. Yip2, Alice Hwe2, Alice Pressman3 and Andy L. Avins3, 1Kaiser Permanente, Richmond, CA, 2Pharmacy, Kaiser Permanente, Oakland, CA, 3Division of Research, Kaiser Permanente, Oakland, CA

Meeting: 2012 ACR/ARHP Annual Meeting

Keywords: gout

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Title: Metabolic and Crystal Arthropathies: Clinical

Session Type: Abstract Submissions (ACR)

Background/Purpose: Effective treatment for recurrent gout has been hampered by a number of problems including outdated treatment approaches, a failure to treat to target, and poor medication adherence by patients. To address these shortcomings, we set up referral-based gout management clinic and made it available to primary care physicians at a single Kaiser Permanente Medical Center. Patients deemed appropriate for uric acid lowering treatment were referred by their primary care physicians to the clinic. 

Methods: The gout management clinic is a pharmacist-staffed, protocol-based program. The pharmacist, under the supervision of a Board Certified Rheumatologist, initiates and/or adjusts urate-lowering medications and monitored lab parameters and clinical course. The protocol employs standard gout medications (including medicatons to prevent and treat gout flares) and laboratory monitoring to achieve and maintain a serum uric acid (SUA) level of 6.0 or less. Patients are monitored until a target SUA ismaintained for at least 3 months prior to discharge from the clinic.  

Results: Results for the first 100 consecutive patients enrolled in this ongoing clinic are reported here.  To date, a SUA of 6.0 or less has been achieved in 67 patients, and no serious adverse reactions have been seen.  The mean pre-treatment SUA was 9.3+/- 1.9 mg/dl, and the average (most recent or final) SUA with treatment is 5.9 +/-1.4 mg/dl   .  Thirty-five patients have already completed the program and have been discharged back to their primary care physicians. Of these, 29 were on allopurinol at a mean dose of 314 mg/day.  (Range 100-750 mg).  The remaining patients, were on febuxostat (3 patients and probenecid (2 patients).

Conclusion: These results show that recurrent gout can be effectively and safely managed by a protocol based population management program. This approach was efficient and required a minimal time commitment on the part of the supervising rheumatologist.


Disclosure:

R. D. Goldfien,
None;

M. S. Ng,
None;

G. M. Yip,
None;

A. Hwe,
None;

A. Pressman,
None;

A. L. Avins,
None.

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2012 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/feasibility-of-using-a-pharnacist-based-gout-management-clinic-to-improve-serum-uric-acid-in-gout-patients-an-a-large-prepaid-health-plan/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology